DailyIQ
|
Sector:HealthcareAll sectors
Last updated 100 days ago

RPRX·RPRX

$.
+. (+.%)
After Hours
High
$45.91
Open
$44.84
Market Cap
26.02B
52W High
$45.91
Low
$44.71
P. Close
$44.80
P/E
34.01
52W Low
$29.66
Fwd P/E
-
Mean Target
-
Technical Score (1D)
95
BUY
News Sentiment
68
BULLISH
Royalty Pharma (RPRX) is attracting attention following its Q4 2025 earnings report. While adjusted EPS of $1.47 beat estimates, sales of $622 million missed expectations, creating a mixed picture for investors. The company's 2026 guidance projects continued growth, with portfolio receipts expected between $3.275 billion and $3.425 billion, despite anticipated headwinds. This comes after a year of strong performance, including double-digit growth in portfolio and royalty receipts, and the internalization of its external manager, which is expected to reduce costs. However, the market reaction to the earnings has been mixed, with shares dipping despite the positive 2026 outlook. Major banks, including UBS and Citi, have issued bullish ratings on RPRX, which may indicate a positive outlook. Traders should monitor how the market digests these mixed results and the impact of the earnings on the stock.
Earnings Summary
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States, within the Healthcare sector, specifically the Biotechnology industry. The company's portfolio includes royalties on marketed therapies and development-stage product candidates across various therapeutic areas. In Q4 2025, the company reported an EPS of $1.46 on revenue of $874 million, compared to Q4 2024, which saw an EPS of $1.1511 on revenue of $742 million. The company's revenue and EPS have shown growth, with Q4 2025 showing an increase in both EPS and revenue compared to the previous year. The company beat estimates in both reported quarters. Examining the historical performance, not enough information is available to determine the YoY growth trajectory or any consistent patterns. Recent news indicates that the company's Q4 2025 earnings report showed an adjusted EPS beat, but sales missed expectations, creating a mixed picture for investors. The company's 2026 guidance projects continued growth, with portfolio receipts expected between $3.275 billion and $3.425 billion. Investors should watch for the upcoming Q1 2026 earnings report to see if the company can maintain its revenue growth trajectory, and the market's reaction to the mixed results and the impact of the earnings on the stock.

EPS

EstBeatMiss
$0.99$1.13$1.26$1.39$1.52Q4'24Q4'25Q1'26
QtrEstActual+/−
Q1'26$1.24$1.30+5.1%
Q4'25$1.15$1.46+27.0%
Q4'24$1.05$1.15+9.2%

Revenue

EstBeatMiss
$664M$833M$1.0B$1.2B$1.3BQ4'24Q4'25Q1'26
QtrEstActual+/−
Q1'26$1.3B$925M-26.6%
Q4'25$859M$874M+1.7%
Q4'24 - $742M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RPRX Stock Snapshot

RPRX is currently trading at $45.18, giving RPRX a market cap of 26.02B and a P/E ratio of 34.0. Today's range spans $44.71–$45.91, with shares opening at $44.84 and moving up $0.38 (0.8%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 68/100.

Over the past year RPRX has traded between $29.66 and $45.91 - the current price is +52.3% off the 52-week low and -1.6% from the high.

Growth-oriented Healthcare investors looking for technical confirmation find it in RPRX: BUY signal, 95/100 score, bullish sentiment at 68/100, price $45.18 (near 52-week highs). The current P/E ratio stands at 34.0. The 26.02B market cap is the sweet spot - big enough to absorb institutional sizing, small enough to move materially on conviction. Annual range: $29.66–$45.91.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (95/100) and news sentiment (68/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $45.18 (near 52-week highs), RPRX's position within the $29.66–$45.91 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…